Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Increase in Short Interest

Posted by on May 28th, 2026

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 47,507 shares, a growth of 1,454.0% from the April 30th total of 3,057 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 651,410 shares, the days-to-cover ratio is presently 0.1 days.

Daiichi Sankyo Stock Down 0.7%

Shares of DSNKY stock opened at $16.81 on Thursday. Daiichi Sankyo has a 12 month low of $15.56 and a 12 month high of $28.21. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. The firm has a market cap of $31.84 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 1.21 and a beta of -0.25. The stock has a 50 day moving average of $17.47 and a 200-day moving average of $19.64.

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo had a return on equity of 15.74% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities analysts predict that Daiichi Sankyo will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Get Our Latest Analysis on DSNKY

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.

Read More

Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.